ArticleHealth and quality of life outcomes2008
Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?
Article in Health and quality of life outcomes, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Surgery for early structural osteoarthritis of the hip and knee: the SCORE evidence synthesis and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee.PloS one · 2017Pooled it
- Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.PharmacoEconomics · 2012Pooled it
- Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.JCO clinical cancer informatics · 2022Trial
- Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.PharmacoEconomics · 2026Article
- How to Assess Health Gains.Healthcare (Basel, Switzerland) · 2025Article
- Obtaining EQ-5D-3L utility index from the health status scale of traditional Chinese medicine (TCM-HSS) based on a mapping study.Health and quality of life outcomes · 2022Article
- Cost-effectiveness of Physical Therapy vs Intra-articular Glucocorticoid Injection for Knee Osteoarthritis: A Secondary Analysis From a Randomized Clinical Trial.JAMA network open · 2022Article
- Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample.PharmacoEconomics · 2019Article
- A brief introduction to health economics.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2019Article
- Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Article
- Article
- Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.PharmacoEconomics · 2016Article
- Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain.BMC medical research methodology · 2016Article
- Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC.Health and quality of life outcomes · 2016Article
- Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Article
- Mapping the disease-specific LupusQoL to the SF-6D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015Article
- The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015Article
- A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches.Health and quality of life outcomes · 2014Article
- Using WOMAC Index scores and personal characteristics to estimate Assessment of Quality of Life utility scores in people with hip and knee joint disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMapping has been used to convert scores from condition-specific measures into utility scores, and to produce estimates of cost-effectiveness. We sought to compare the QALY gains, and incremental cost per QALY estimates, predicted on the basis of mapping to those based on actual EQ-5D scores.
methodsIn order to compare 4 different interventions 389 individuals were asked to complete both the EQ-5D and the Western Ontartio and McMaster Universities Osteoarthritis Index (WOMAC) at baseline, 6, 12, and 24 months post-intervention. Using baseline data various mapping models were developed, where WOMAC scores were used to predict the EQ-5D scores. The performance of these models was tested by predicting the EQ-5D post-intervention scores. The preferred model (that with the lowest mean absolute error (MAE)) was used to predict the EQ-5D scores, at all time points, for individuals who had complete WOMAC and EQ-5D data. The mean QALY gain associated with each intervention was calculated, using both actual and predicted EQ-5D scores. These QALY gains, along with previously estimated changes in cost, were also used to estimate the actual and predicted incremental cost per QALY associated with each of the four interventions.
resultsThe EQ-5D and the WOMAC were completed at baseline by 348 individuals, and at all time points by 259 individuals. The MAE in the preferred model was 0.129, and the mean QALY gains for each of the four interventions was predicted to be 0.006, 0.058, 0.058, and 0.136 respectively, compared to the actual mean QALY gains of 0.087, 0.081, 0.120, and 0.149. The most effective intervention was estimated to be associated with an incremental cost per QALY of pound6,068, according to our preferred model, compared to pound13,154 when actual data was used.
conclusionWe found that actual QALY gains, and incremental cost per QALY estimates, differed from those predicted on the basis of mapping. This suggests that though mapping may be of value in predicting the cost-effectiveness of interventions which have not been evaluated using a utility measure, future studies should be encouraged to include a method of actual utility measurement.
trial registrationCurrent Controlled Trials ISRCTN93206785.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.